返回
Efficient Augmented Intelligence Framework for Bladder Lesion Detection
DOI:10.1200/CCI.23.00031.png)
摘要
En 中文
PURPOSE Development of intelligence systems for bladder lesion detection is cost intensive. An efficient strategy to develop such intelligence solutions is needed. MATERIALS AND METHODS We used four deep learning models (ConvNeXt, PlexusNet, MobileNet, and SwinTransformer) covering a variety of model complexity and efficacy. We trained these models on a previously published educational cystoscopy atlas (n = 312 images) to estimate the ratio between normal and cancer scores and externally validated on cystoscopy videos from 68 cases, with region of interest (ROI) pathologically confirmed to be benign and cancerous bladder lesions (ie, ROI). The performance measurement included specificity and sensitivity at frame level, frame sequence (block) level, and ROI level for each case. RESULTS Specificity was comparable between four models at frame (range, 30.0%-44.8%) and block levels (56%-67%). Although sensitivity at the frame level (range, 81.4%-88.1%) differed between the models, sensitivity at the block level (100%) and ROI level (100%) was comparable between these models. MobileNet and PlexusNet were computationally more efficient for real-time ROI detection than ConvNeXt and SwinTransformer. CONCLUSION Educational cystoscopy atlas and efficient models facilitate the development of real-time intelligence system for bladder lesion detection.
Keyword:
CYSTOSCOPY
CANCER
HEXAMINOLEVULINATE
RECURRENCE
期刊
J
IF:
2.8
论文数:
669
被引数:
2.4K
机构
引用论文
MEMS based multi-band Energy Harvesting for Wireless Sensor Network applications基于MEMS的多频带能量收集在无线传感器网络中的应用
Desempenho de crianças do ensino fundamental na solução de problemas aritméticos<A NAME="top"></A>问题的基本解决方案
A nationwide prospective cohort study on return to gainful occupation after stroke in Denmark 1996–2006
BMJ Open
IF0
Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
BJU INTERNATIONAL
IF4.4
Evaluating eligibility criteria of oncology trials using real-world data and AI使用真实世界数据和AI评估肿瘤学试验的资格标准
NATURE
IF48.5


